US researchers have revealed(link is external) the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them.
The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.
“This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.
“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.
The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.
Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.
“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.
Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.
In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.
Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.
The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- Guidelines for Gastric and Esophageal Cancers Expand to Include NGS, Immunotherapieson May 15, 2021 at 5:08 am
The latest updates on gastric and esophageal cancers focus on greater use of biomarkers, next-generation sequencing (NGS), and immunotherapies.
- YOUR HEALTH: New treatments for melanomaon May 14, 2021 at 4:30 pm
Over the past few years, immunotherapies have been effective for some patients, but researchers are now testing a new therapy for patients with advanced melanoma that has been tough to treat. They've ...
- Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate Progresson May 14, 2021 at 1:50 pm
Kiromic BioPharma achieved important scientific and operational milestones during the year that we believe have us well positioned for preparing our staff and our facilities for the first in-human ...
- Immunotherapy Could “Provide A Whole New Realm” For Patients with Myelomaon May 14, 2021 at 11:18 am
New advances in research around immunotherapies for patients with myeloma are on the horizon, according to an expert from the HealthTree Foundation & Myeloma Crowd.
- Global Allergy Immunotherapies Market to grow by USD 713.56 million|Key Drivers and Market Forecasts|17000+ Technavio Research Reportson May 13, 2021 at 6:00 pm
The allergy immunotherapies market is poised to grow by USD 713.56 million during 2021-2025, progressing at a CAGR of almost 8% during ...
- NextUp: The Philly Biotech Company Advancing Cancer Cell Therapy Through Bone Marrowon May 12, 2021 at 1:20 pm
WindMIL Therapeutics is targeting marrow-infiltrating lymphocytes (MILs) to create a treatment to destroy cancer cells in patients, no matter their tumor type.
- Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasison May 12, 2021 at 6:05 am
Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, ...
- Immunocore Reports First Quarter 2021 Financial Resultson May 12, 2021 at 6:00 am
PRESS RELEASE ImmunocoreReports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug ...
- IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipelineon May 12, 2021 at 4:05 am
IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results ...
- Immunotherapy for hard-to-treat cancers ready to move toward clinical trialson May 7, 2021 at 9:59 am
Immunotherapies that fight cancer have been a life-saving advancement for many patients, but the approach only works on a few types of malignancies, leaving few treatment options for most cancer ...
via Bing News